Press Releases

Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. announced today a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II). Hunter syndrome is caused by a deficienc

The Agency for Science, Technology and Research has developed an Automated Vaccine Inoculation Dispenser (AVID) system, which replaces the manual step of filling injection syringes with vaccine liquid. AVID is customised for the vaccination centres which are set up by the Ministry of Health and operated by private healthcare providers. AVID was designed to address the labour-intensive steps of the vaccination process to reduce the workload of healthcare providers, increase accuracy

Medable Inc., the leading cloud platform for patient-centered drug development, today announced its Site Network Council (SNC), a select group of clinicians and research leaders who will serve as influential voices in Medable product and services development. SNC members represent diverse clinical sites and provide real-world experience and insights to inform Medable technical and strategic direction. They offer a transparent window into modern research environments to help Medable create dec

Appili Therapeutics Inc. a biopharmaceutical company focused on drug development for infectious diseases, and AiPharma Global Holdings LLC (“AiPharma”), a private pharmaceutical research, development and commercialization company, today announced a strategic alliance to advance the global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral currently being evaluated by Appili and its global consortium of partners for the potential treatment and

Sun Pharmaceutical Industries Ltd. today announced the launch of a novel formulation in cough management - Chericof® 12 (Dextromethorphan Hydrobromide 30 mg and Chlorpheniramine Maleate 4 mg) in India. Chericof® 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug. Chericof® 12 is approved for patients of age group six years and above. All cough syrups generall

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has reached an agreement with the Attorney General (AG) of Louisiana that settles the state’s opioid-related claims. The agreement is contingent on confirmation from the state by November 2, 2021 that all political subdivisions will release Teva as part of the settlement. Under the terms of the settlement, Teva will pay Louisiana $15 million over an 18-year time period and will provide an additional

ProBioGen today announced the closing of a DirectedLuck Transposase Technology research license agreement with another global biopharma company. The license covers the evaluation of the DirectedLuck Transposase technology in their cell line development processes. DirectedLuck builds on a transposase's principle but with additional major improvements. It has been optimized to recognize specific chromatin marks, guiding the transgene to genomic regions with highest transcriptional

ANP Technologies Inc. (“ANP”) announced that it has received Emergency Use Authorization (EUA) for its NIDS® COVID-19 Antigen Rapid Test Kit from the U.S. Food and Drug Administration (FDA). The test, providing a visual result in 15 minutes, is a lateral flow immunoassay (LFA) based on ANP’s Nano-Intelligent Detection System (NIDS) platform technology. The NIDS® COVID-19 Antigen Rapid Test is a highly sensitive test for the detection of SARS-CoV-2 nucleocap

Pfizer Inc. announced that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose quadrivalent mRNA vaccine against influenza in healthy adults. Pfizer’s mRNA influenza vaccine program is the first in a planned wave of programs leveraging mRNA technology for influenza. Beyond influenza, the company plans to explore mRNA in other respiratory viruses, including medically appropriate vaccines combinations

Cell culture laboratories working with CO2 incubators and water baths can now benefit from a new product designed to help safeguard incubators from water-borne contaminants, saving scientists time and labor while reducing the need for hazardous chemical solutions. When placed into any CO2 incubator water pan or laboratory water bath, the Thermo Scientific Aqua-Tec Water Preservation Cell provides continuous protection from waterborne microorganisms for up to six months. The 9.4cm ce